摘要
目的 研究肾脏移植术后高脂血症同转化生长因子 β及其受体mRNA表达之间的关系 ,探讨其导致慢性移植肾病的可能机制与防治措施。方法 肾移植术血脂正常组、血脂增高组及正常对照组各 30例 ,血脂增高组应用辛伐他汀 2 0mg/d进行降脂治疗 ,于服药后 1.5及 3个月复查血脂 ;同时于不同时段应用逆转录聚合酶链反应检测外周血单个核细胞转化生长因子β及其受体mRNA表达。 结果 血脂增高组患者血清总胆固醇、甘油三酯、低密度脂蛋白胆固醇水平均显著高于血脂正常组及正常对照组 (P =0 .0 0 0 ) ,辛伐他汀降脂治疗 1.5及 3个月后血清总胆固醇、甘油三酯、低密度脂蛋白胆固醇水平呈递减趋势 ,且有显著差异 (P值分别为 0 .0 0 0、0 .0 0 0、0 .0 2 7) ;外周血单个核细胞转化生长因子β及其受体mRNA表达水平按正常对照组、血脂正常组、血脂增高组的顺序递增 ,血脂增高组患者于辛伐他汀治疗后随血脂的下降呈逐步下降趋势。结论 肾移植患者高脂血症可导致转化生长因子 β及其受体mRNA表达水平上调 ,可能是高脂血症引起动脉硬化、慢性移植肾病的机制之一 ;辛伐他汀降脂治疗可使转化生长因子 β及其受体的表达下调 。
Aim Transforming growth factor β1 (TGF β1) and hyperlipidemia are involved in the pathogenesis of chronic allograft nephropathy (CAN) and atherosclerosis post renal transplantation. In this study, the mRNA expressions of TGF β1 and its receptor TGF β R3 were measured to investigate the mRAN expressions of MCP-1 and CCR2 in peripheral blood monocyte cells of renal transplant recipients and the influence by Simvastatin treatment. Methods Sixty recipients were selected from 167 renal transplant recipients and divided into group without hyperlipidemia (n=30) and hyperlipidemia group (n=30). Control group consists of 30 healthy volunteers. The patients with hyperlipidemia were treated with Simvastatin for 3 months. The mRNA expressions of TGF β1 and TGF β R3 were detected with reverse transcription-polymerase chain reaction (RT-PCR). Results The serum lipid levels and the mRNA expression of TGF β1 and TGF β R3 in renal transplant recipients were significantly higher than that in controls. The mRNA expression of TGF β1 and TGF β R3 in patients with hyperlipidemia were more significantly higher than that in the patients without hyperlipodemia (P=0.000), and the serum lipid levels and the mRNA expression of TGF β1 and TGF β R3 decreased gradually at 1.5 months and 3 months after treated with Simvastatin. Conclusions Hyperlipidmia in renal transplantrecipients might result in upregulated mRNA expression of TGF β1 and TGF β R3 in renal transplant recipients, Simvastatin treatment may decrease the serum lipid levels and the mRNA expression of TGF β1 and TGF β R3 in peripheral mononuclear cells, and it may be one of the important mechanism to prevent CAN and atherosclerosis in renal recipients with hyperlipidemia.
出处
《中国动脉硬化杂志》
CAS
CSCD
2005年第1期65-68,共4页
Chinese Journal of Arteriosclerosis
